Reneo Pharmaceuticals (NASDAQ:RPHM) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.62) by 12.9 percent. This is a 25 percent decrease over losses of $(0.56) per share from the same period last year.
Reneo Pharmaceuticals Q4 GAAP EPS $(0.70) Misses $(0.62) Estimate; Cash, Cash Equivalents, And Short-term Investments Of $103M
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.